<DOC>
	<DOCNO>NCT01476046</DOCNO>
	<brief_summary>The main purpose study see safe GSK1995057 well tolerate dose . The study also investigate GSK1995057 take , metabolise ( chemically break ) , distribute body excrete , effect study drug .</brief_summary>
	<brief_title>Safety Study GSK1995057 Given Single Repeat Intravenous Doses Healthy Subjects .</brief_title>
	<detailed_description>This study first investigation GSK1995057 human primarily design investigate safety tolerability single repeat intravenously infused dos . The study enrol healthy male subject healthy female subject non-child bearing potential also investigate immunogenicity , GSK1995057 distribution ( pharmacokinetics ) , potential impact indicator host immunity normal immunological function . Safety , tolerability , immunogenicity , pharmacokinetic pharmacodynamic data trial may facilitate clinical investigation healthy subject dose GSK1995057 via inhaled route , ultimately clinical trial patient acute lung injury .</detailed_description>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Healthy determine responsible experienced physician . Male female 18 55 year age inclusive A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation , hysterectomy bilateral oophorectomy ; postmenopausal define 12 month spontaneous amenorrhea elevate FSH per local laboratory guideline . Normal creatinine clearance value screen Male subject must agree use one study specific contraception method Body weight â‰¥ 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) . Normal lung function screening . Capable give write informed consent , include compliance requirement restriction list consent form . Available complete study assessment . Able read , comprehend write English sufficient level complete study elate material . A history Hepatitis B , Hepatitis C HIV infection and/or positive prestudy HIV , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality . ( With exception know Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . Evidence previous active mycobacterium tuberculosis complex infection Recent history and/or positive test Toxoplasma consistent active oxoplasmosis infection . A positive test influenza A/B take within 7 day dose . Current evidence history influenzalike illness . Corrected QT interval ( QTcF ) &gt; 450msec ECG reading . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol follow use guide : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject unwilling abstain alcohol consumption 24 hr prior dose discharge clinic , 24 hr prior outpatient clinic visit . Subjects smoke history &gt; 10 cigarette per day last 3 month . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) exposure four new chemical biological entity within 12 month prior first dose day . Subjects receive type vaccination within 3 week anticipate dose start expect vaccinate within 3 week last dose . Current evidence ongoing acute infection , history repeat chronic significant infection history serious infection within three month dose . Subjects asthma history asthma , COPD , respiratory condition recurrent infection ( subject suffer childhood asthma adult may include provide fulfil entry criterion ) . Subjects know history migraine headache frequently suffer type headache require medication ( frequent define one headache fortnight ) . Use prescription nonprescription drug ( except simple analgesic ) , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy include severe allergic reaction , angioedema anaphylaxis , opinion investigator sponsor Medical Monitor , contraindicate participation . History malignancy , except adequately treated noninvasive cancer skin ( basal squamous cell ) cervical carcinoma situ ( &gt; 2 yr prior dose ) . Where participation study would result donation blood blood product excess 500 mL within 3 month 90 day period . Subject unable refrain travel country high prevalence TB area prevalent infectious disease judge investigator sponsor medical monitor start screen final followup visit . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Lung Injury ( ALI )</keyword>
	<keyword>Acute Respiratory Distress Syndrome ( ARDS )</keyword>
</DOC>